Andreas Wetscherek

Andreas Wetscherek

Auto-generated profile, based on publicly available information

Andreas Wetscherek

Joint Department of Physics The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2024
Verified
Conference Paper
Open access
NYNur Yildirim
Nur Yildirim
HRHannah Richardson
Hannah Richardson
MWMaria Teodora Wetscherek
Maria Teodora Wetscherek
JBJunaid Bajwa
Junaid Bajwa
JJJoseph Jacob
Joseph Jacob
Anja ThiemeAnja Thieme
Anja Thieme
Recent advances in AI combine large language models (LLMs) with vision encoders that bring forward unprecedented technical capabilities to leverage for a wide range of healthcare applications. Focusing on the domain of radiology, vision-language models (VLMs) achieve good performance results for tasks such as generating radiology findings based on a patient’s medical image, or answering visual questions (e.g., “Where are the nodules in this chest X-ray?”). However, the clinical utility of potential applications of these capabilities is currently underexplored. We engaged in an iterative, multidisciplinary design process to envision clinically relevant VLM interactions, and co-designed four VLM use concepts: Draft Report Generation, Augmented Report Review, Visual Search and Querying, and Patient Imaging History Highlights. We studied these concepts with 13 radiologists and clinicians who assessed the VLM concepts as valuable, yet articulated many design considerations. Reflecting on our findings, we discuss implications for integrating VLM capabilities in radiology, and for healthcare AI more generally.

2 October 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
EKErnst Kooreman
Ernst Kooreman
PHPetra J. van Houdt
Petra J. van Houdt
RKRick Keesman
Rick Keesman
FPFloris J. Pos
Floris J. Pos
VPVivian W.J. van Pelt
Vivian W.J. van Pelt
UHUulke A. van der Heide
Uulke A. van der Heide

16 March 2016 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
CRChristopher M. Rank
Christopher M. Rank
THThorsten Heußer
Thorsten Heußer
MBMaria T. A. Buzan
Maria T. A. Buzan
AWAndreas Wetscherek
Andreas Wetscherek
MFMartin T. Freitag
Martin T. Freitag
MKMarc Kachelrieß
Marc Kachelrieß


31 July 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
MGMarianne Geilswijk
Marianne Geilswijk
MGMaurizio Genuardi
Maurizio Genuardi
EWEmma R. Woodward
Emma R. Woodward
KNKatie Nightingale
Katie Nightingale
JHJazzmin Huber
Jazzmin Huber
JBJoan Brunet
Joan Brunet
Birt-Hogg-Dubé syndrome (BHD syndrome) is an autosomal dominant multisystem disorder with variable expression due to pathogenic constitutional variants in the FLCN gene. Patients with BHD syndrome are predisposed to benign cutaneous fibrofolliculomas/trichodischomas, pulmonary cysts with an associated risk of spontaneous pneumothorax, and renal cell carcinoma. A requirement for updated International consensus recommendations for the diagnosis and management of BHD syndrome was identified. Based on a comprehensive literature review and expert consensus within the fields of respiratory medicine, urology, radiology, dermatology, clinical oncology and clinical genetics, updated recommendations for diagnosis, surveillance and management in BHD syndrome were developed. With the widespread availability of FLCN genetic testing, clinical scenarios in which a diagnosis should be considered and criteria for genetic testing were defined. Following a clinical and/or molecular diagnosis of BHD syndrome, a multidisciplinary approach to disease management is required. Regular renal cancer surveillance is recommended in adulthood and life-long, but the evidence base for additional tumour surveillance is limited and further research warranted. Recommendations for the treatment of cutaneous, pulmonary and renal manifestations are provided. Awareness of BHD syndrome needs to be raised and better knowledge of the clinical settings in which the diagnosis should be considered should enable earlier diagnosis. Further details, including areas for future research topics are available at: https://www.genturis.eu/l=eng/Guidelines-and-pathways/Clinical-practice-guidelines.html.

21 September 2022 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
RGRosie J. Goodburn
Rosie J. Goodburn
MPMarielle Philippens
Marielle Philippens
TLThierry L. Lefebvre
Thierry L. Lefebvre
AKAly Khalifa
Aly Khalifa
TBTom Bruijnen
Tom Bruijnen
OGOliver Gurney-Champion
Oliver Gurney-Champion
Radiation therapy is a major component of cancer treatment pathways worldwide. The main aim of this treatment is to achieve tumor control through the delivery of ionizing radiation while preserving healthy tissues for minimal radiation toxicity. Because radiation therapy relies on accurate localization of the target and surrounding tissues, imaging plays a crucial role throughout the treatment chain. In the treatment planning phase, radiological images are essential for defining target volumes and organs‐at‐risk, as well as providing elemental composition (e.g., electron density) information for radiation dose calculations. At treatment, onboard imaging informs patient setup and could be used to guide radiation dose placement for sites affected by motion. Imaging is also an important tool for treatment response assessment and treatment plan adaptation. MRI, with its excellent soft tissue contrast and capacity to probe functional tissue properties, holds great untapped potential for transforming treatment paradigms in radiation therapy. The MR in Radiation Therapy ISMRM Study Group was established to provide a forum within the MR community to discuss the unmet needs and fuel opportunities for further advancement of MRI for radiation therapy applications. During the summer of 2021, the study group organized its first virtual workshop, attended by a diverse international group of clinicians, scientists, and clinical physicists, to explore our predictions for the future of MRI in radiation therapy for the next 25 years. This article reviews the main findings from the event and considers the opportunities and challenges of reaching our vision for the future in this expanding field.